Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patientsâ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a pipeline of three independent, rare disease endocrinology product candidates in clinical development, and has established oncology as its second therapeutic area of focus. Source
No articles found.
Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...
Exicure, Inc. is a clinical stage biotechnology...
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials compa...
PolarityTE is a commercial-stage biotechnology ...
Microbotâ˘, which was founded in 2010 and commenced operations in 2011, became a ...
Microbotâ˘, which was founded in 2010 and comm...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing an...
Aeterna Zentaris is a specialty biopharmaceutic...
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused ...
Millendo Therapeutics is a late-stage biopharma...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
Join the National Investor Network and get the latest information with your interests in mind.